CD19+ B Cells

About CD19+ B Cells

Human CD19+ B Cells for Immunology, Antibody and B Cell Therapy Research

Human CD19+ B cells are purified from the peripheral blood of IRB-consented healthy and clinically confirmed disease-state donors, processed within 24 hours of collection and cryopreserved in CryoStor CS10 media. These cells support studies of B cell biology, antibody production, B cell receptor signalling, immune regulation and disease-associated immune dysfunction.

Whether your team needs healthy donor controls, disease-state CD19+ B cells, or custom donor-defined programs, Sanguine helps researchers source human CD19+ B cells aligned to protocol requirements and downstream assay needs.

Why Isolated CD19+ B Cells Rather Than Bulk PBMC

• CD19 is expressed across essentially the whole B lineage, from the pro-B stage through mature B cells and into plasmablasts. That breadth is the reason it is the standard pan-B selection marker, and it is also why CD19 selection captures plasmablast populations that CD20-based selection or CD20-directed depletion largely miss.
• CD19 is not merely a marker. It functions as a B cell receptor co-receptor, associating with CD21 and CD81 and lowering the threshold for BCR-driven activation, so CD19 itself sits within the signalling biology researchers are usually trying to measure.
• B cells are a minority of circulating lymphocytes, so functional readouts in bulk PBMC are diluted and often confounded by monocyte and T cell activity. Positive or negative selection to a defined CD19+ population gives interpretable per-cell measurements of proliferation, differentiation and antibody secretion.
• The B compartment is functionally heterogeneous, spanning naive, unswitched and class-switched memory, transitional, atypical or double-negative, regulatory and plasmablast subsets. Starting from a purified CD19+ population makes downstream subset sorting and high-parameter phenotyping far more efficient.
• CD19 is the target antigen for approved CD19-directed CAR T cell products and bispecific T cell engagers, which makes primary human CD19+ B cells directly relevant as target cells for potency, cytotoxicity and antigen-density assays.
• Purified B cells are the correct substrate for BCR repertoire sequencing, class-switch recombination and somatic hypermutation studies, and for BTK, SYK and PI3K inhibitor pharmacology, where contaminating cell types would obscure the signal.

Donor Stratification Available

• Healthy donor controls, including age- and sex-matched cohorts
• Disease-state donors across autoimmune, immune-mediated inflammatory, allergic, infectious and oncology indications
• Demographics: age range, sex assigned at birth, race and ethnicity
• Treatment status, including B cell depleting or immunomodulatory therapy exposure, which materially affects B cell yield and subset composition
• Serology and infectious disease screening results where documented, plus HLA typing on request
• Matched autologous PBMC, plasma, serum and other isolated immune cell fractions from the same donor

Product Features

• Research use only human CD19+ B cells
• Isolated from healthy and disease-state donors
• High purity and viability (≥90% CD19+ cells) to support downstream research applications; values reported per lot
• Cryopreserved using CryoStor CS10 media
• Processed within 24 hours of collection
• IRB-approved protocols and HIPAA-compliant handling
• Available in standard vial sizes with custom sourcing support
• Suitable for immunology, autoimmune, infectious disease and therapeutic research workflows

Donor Metadata

Available donor-level information helps researchers select CD19+ B cell samples that align to study design and population requirements.

• Donor screening and verified health or disease-state status where applicable
• Demographic data including age, sex assigned at birth, and race/ethnicity
• Medication and allergy history available
• Additional donor-level information may be available upon request
• Study-specific donor requirements may be supported for custom programs

Applications

Human CD19+ B cells support a wide range of immune-cell research and translational workflows.

• Antibody production, class-switching and somatic hypermutation studies
• B cell receptor signalling and immune activation analysis
• BTK, SYK and PI3K inhibitor pharmacology
• BCR repertoire sequencing and clonality analysis
• B cell subset immunophenotyping and functional immune assays
• Target cells for CD19-directed CAR T and bispecific engager potency assays
• Autoimmune disease and immunodeficiency modelling
• Biomarker discovery and therapeutic target validation

Related Immune Cell and Source Specimen Types

• Healthy CD19+ B Cells
• Human CD4+ T Cells
• Human CD8+ T Cells
• Human PBMC
• Human Leukopak
• Human Whole Blood

Compliance and Quality Assurance

• IRB-approved collections with 21 CFR Part 11-compliant e-consent
• Standardized isolation, processing, and cryopreservation workflows
• HIPAA-compliant donor data protection
• Quality-focused handling designed to support cell integrity and downstream use
• Documentation available upon request for qualified research programs

Ordering & Customization

Human CD19+ B cells are available in standard cryopreserved vial sizes and may also be supported through custom sourcing programs. If your study requires disease-state donors, custom donor criteria, international shipping, or regulatory documentation, our team can help identify the best path forward. For a biology and subsets overview, read our guide to human CD19+ B cells.

For pricing, current availability, or a quote on a stratified donor cohort, and for international shipping, documentation or regulatory support, please contact learnmore@sanguinebio.com. To review the source material these cells are isolated from, visit our human PBMC and human leukopak pages.